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http://dx.doi.org/10.1016/j.ccell.2014.10.010SUMMARYSmall noncodingmiRNAs represent underexplored targets of genomic aberrations and emerging therapeutic
targets. The 3q26.2 amplicon is among the most frequent genomic aberrations in multiple cancer lineages
including ovarian and breast cancers. We demonstrate that hsa-miR-569 (hereafter designated as
miR569), which is overexpressed in a subset of ovarian and breast cancers, at least in part due to the
3q26.2 amplicon, alters cell survival and proliferation. Downregulation of TP53INP1 expression by miR569
is required for the effects of miR569 on survival and proliferation. Targeting miR569 sensitizes ovarian and
breast cancer cells overexpressing miR569 to cisplatin by increasing cell death both in vitro and in vivo.
Thus targeting miR569 could potentially benefit patients with the 3q26.2 amplicon and subsequent
miR569 elevation.Significance
DNA copy number aberrations (CNAs) drive tumorigenesis acro
ing a discrete set of genes, others such as the 3q26.2 amplicon
cers and 15% of breast cancers, primarily in aggressive basa
are broad and likely contain multiple driver aberrations. We de
with subsequent decreases in TP53INP1, contributing to pro
in vivo. Thus, miR569 and its target TP53INP1 are promising c
Cass cancer lineages. Although someCNAs are narrow, target-
, which is present in35%of high-grade serous ovarian can-
l-like breast tumors, as well as several other tumor lineages,
monstrate that the 3q26.2 amplicon increases miR569 levels
liferation and survival of epithelial cancer cells in vitro and
andidate biomarkers and therapeutic targets.
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miR569 Aberration in Epithelial OncogenesisINTRODUCTION
Genomic instability, including DNA copy number aberrations
(CNAs), is a hallmark of cancer. Noncoding genes represent po-
tential targets of CNAs and cancer drivers (Esquela-Kerscher
and Slack, 2006). Thus, characterization of alteredmiRNA result-
ing from CNAs could improve our understanding of tumor initia-
tion and progression as well as provide molecular markers for
early detection, prognosis and response prediction, and targets
for therapy. Both high-grade serous ovarian cancer and basal-
like breast cancer, the most aggressive forms of ovarian and
breast cancers, appear to be driven by CNAs (Cancer Genome
Atlas Research Network, 2011, 2012; Ciriello et al., 2013). Ampli-
fication of chromosome 3q26.2 is a common event in ovarian
(Eder et al., 2005) and breast cancers (Weber-Mangal et al.,
2003). The 3q26.2 amplicon is large and structurally complex
consistent with multiple components of the amplicon contrib-
uting to tumor initiation and progression either alone or through
cooperative activity. We have demonstrated that the 3q26.2
CNA leads to amplification and aberrant function of PIK3CA,
PKCI, SKIL, and MECOM (Eder et al., 2005; Nanjundan et al.,
2008).
RESULTS
Amplification of 3q26.2 Is Associated with Increased
Expression of miR569
To better define aberration within the 3q26 region, we used high-
resolution SNP-based copy number analysis of 533 high-grade
serous epithelial ovarian cancers and 841 breast cancers from
The Cancer Genome Atlas (TCGA). At least one copy of 3q26.2
was gained in approximately 35%of high-grade serous epithelial
ovarian cancers (Figure 1A) and 15% of breast cancers (Figures
S1A and S1B available online). In addition to expression of
genes located at 3q26.2 being increased, our results demon-
strate that miR569 expression was increased as a consequence
of the 3q26.2 amplicon. Quantitative real-time PCR (qRT-PCR)
analysis of 33 ovarian cancer samples demonstrated a marked
increase in mature miR569 in 18/24 tumors with the 3q26.2
amplicon (more than four copies), relative to 0/9 nonamplified tu-
mors (Figure 1B; Figure S1C). The association of mature miR569
levels with 3q26.2 amplification (more than three copies) was
confirmed in ovary and breast epithelial cell lines including
immortalized normal cell lines (Figures 1C and 1D). Importantly,
miR569 was highly expressed in ovarian cancers compared to
normal ovary or fallopian tube (Figure 1E). Thus, miR569 expres-
sion is likely dysregulated as a consequence of the 3q26.2 am-
plicon. However, additional mechanisms may be involved in
the regulation of miR569 levels because not all tumors with the
3q26.2 amplicon have elevated miR569.
To identify regulators of miR569, mRNAs most positively
correlated with miR569 in a public data set (Bentink et al.,
2012) were used to develop a gene protein interaction map in
the Netwalker gene network analysis suite (Komurov et al.,
2012) (Table S1; Figure S1D). Among 11 candidate mediators,
target-specific knockdown of NF-kB2 and SPHK1 decreased
miR569 levels (Figures S1E–S1G). Analysis using CHIPBASE
(Yang et al., 2013) was consistent with NF-kB regulating
miR569 expression (Figure S1H). Compatible with a previous864 Cancer Cell 26, 863–879, December 8, 2014 ª2014 Elsevier Inc.report (Liang et al., 2013), we propose that the SPHK1-NF-kB
axis (Figure S1I) and copy number changes of miR569 regulate
miR569 levels.
miR569 Alters Cell Proliferation and Viability of Breast
and Ovarian Cell Lines
Enforced expression of miR569 in the immortalized ovarian
epithelial cell line IOSE-80 and mammary epithelial cell line
MCF10A, which do not have 3q26.2 amplification and exhibit
low miR569 levels (Figure 1C), increased cell proliferation in 2D
cultures (Figure 1F; Figure S1J) and increased the number and
size of spheroids in 3D cultures (Figures 1G and 1H; Figures
S1K and S1L). Importantly, MCF10A stably expressing miR569
demonstrated luminal filling with less caspase-3 activation as
compared to control cells (Figures S1L and S1M). In parallel,
knockdown with anti-miR569 in HEYA8 and OVCAR5 ovarian
cancer cells, which have the 3q26.2 amplicon and elevated
miR569 levels (Figure 1C), increased cleaved PARP and cleaved
caspase 3 (Figure 1I). Furthermore, anti-miR569 reduced the G2
population and increased the G1 population (Figure S1N)
concomitant with a marked increase in a sub G0/G1 population
(Figure S1O) and cell death (Figure S1P). The effect of anti-
miR569 on apoptosis was confirmed using a cell death-specific
ELISA kit (Figure 1J; Figure S1Q). Furthermore, a pan-caspase
inhibitor abolished anti-miR569 induced cell death (Figure 1J).
Altogether, our results suggest that miR569 promotes cell prolif-
eration and inhibits apoptosis.
miR569 Expression Promotes Tumor Growth and
Metastasis In Vivo
To determine whether miR569 alters tumor growth in vivo,
3q26.2 nonamplified IGROV1 ovarian cancer cells (Figure 2A)
or MDAMB231 breast cancer cells (Figure 2B) stably overex-
pressing miR569 or control miR were injected orthotopicallly
into the peritoneal cavity or mammary fat pad of nude mice,
respectively. Enforced expression of miR569 in both breast
and ovarian cancer cells significantly increased tumor growth
and tumor weight (Figures 2C–2F; Figures S2A and S2B).
Ki67 and CD31 levels were significantly elevated in miR569-ex-
pressing IGROV1 and MDAMB231 tumors compatible with in-
creases in cell proliferation and angiogenesis (Figures 2G and
2H; Figures S2C and S2D). Strikingly, the number of peritoneal
implants as well as lung metastases (Figure 2I) were increased
in mice with miR569-expressing IGROV1 tumors and lung me-
tastases were increased in mice with miR569-expressing
MDAMB231 tumors (Figures 2J and 2K). Thus, expression of
miR569 in breast and ovarian cancer cells lacking the 3q26.2
amplicon is sufficient to increase tumor growth, proliferation,
neovascularization, and metastatic capability.
TP53INP1 Is a Direct Target of miR569
To identify targets of miR569 that could alter cell survival, we
used an integrative approach combining microRNA target pre-
dictions from TargetScan (Lewis et al., 2005) (Table S2) and
publicly available human Argonaute crosslinking immunoprecip-
itation (AGO-CLIP) data (Chi et al., 2009; Hafner et al., 2010) that
ranks the relative confidence of miRNA targets by their presence
in 14 AGO-CLIP libraries (Hamilton et al., 2013). miR569 targets
detected inR5 of 14 AGO-CLIP data sets were considered high
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Figure 1. Amplification of 3q26.2 Correlates with miR569 Expression and Increases Proliferation of Ovarian Cancer Cells
(A) Heatmap of copy number alterations of chromosome 3q in 533 ovarian cancer samples. Red arrow indicates the 3q26.2 region.
(B) miR569 expression in ovarian cancer samples (n = 33) assessed by quantitative real-time PCR (qRT-PCR). Box plot represents lower quartile; median and
upper quartile and whiskers represent the 95% confidence interval of the mean. Significance was calculated with Student’s t test.
(C) Expression of miR569 in cell lines assessed by qRT-PCR.
(D) miR569 expression in cell lines presented in Figure 1C. Box plot represents lower quartile; median and upper quartile and whiskers represent the 95%
confidence interval of the mean. Significance was calculated with Student’s t test.
(E) miR569 expression in normal ovarian (N. Ov), fallopian tube (F. T) or ovarian cancer (Ov. Ca) epithelium was analyzed by qRT-PCR and normalized to U6 RNA
(n = 8 per group). Bars represent mean ± SEM. Significance was calculated with Student’s t test.
(F) Cell viability of IOSE-80 and MCF10A transfected with control oligos or miR569 was assessed on day 4 using 3-(4,5-dimethylthiazol-z-yl)-2,5-diphenyl
tetrazolium bromide (MTT). Bars represent SD of quadruplicates. Significance was calculated with Student’s t test.
(G and H) IOSE-80 cells were grown in suspension on low attachment plates for 2 days in low density conditions. Colonies were photographed 4 days after
transfection with control miR or miR569. MCF10A grown onMatrigel for 2 days were infected with lentivirus of humanmiR569 or control miR and allowed to grow
on Matrigel for another 10 days. Spheroids were fixed and photographed. Number (G) and volume (H) of spheroids were calculated using Nikon Elements digital
imaging software. Bars represent SD of images from three different fields.
(I) HEYA8 or OVCAR5 were lysed 48 hr after transfection with control antimiR or anti-miR569 and immunoblotted with indicated antibodies.
(J) Cell death was assessed using Roche’s Cell Death Detection ELISA kit 72 hr after antimiR transfection in presence or absence of pan-caspase inhibitor. Bars
represent SD of quadruplicates. Significance was calculated with Student’s t test.
See also Figure S1 and Table S1.
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miR569 Aberration in Epithelial Oncogenesisconfidence candidates (q < 0.001 based on random permutation
of clusters) (Table S3). High confidence AGO-CLIP targets were
overlaid with putative TargetScan miR569 targets resulting in
17 common targets (Table S4; Figure 3A). Of the 17 candidates
assessed, miR569 markedly decreased TP53INP1 mRNA levelsCain IOSE-80 ovarian epithelial cells (Figure 3B) consistent with
TP53INP1 being a miR569 target. miR569 binding to the 30UTR
of TP53INP1 was identified in six of 14 independent AGO-
CLIP data sets (Figure 3C). Furthermore, miR569 decreased
TP53INP1 protein levels in normal breast and ovarian cellsncer Cell 26, 863–879, December 8, 2014 ª2014 Elsevier Inc. 865
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miR569 Aberration in Epithelial Oncogenesis(Figure 3D), whereas anti-miR569 increased TP53INP1 levels
in HEYA8 and OVCAR5 cells that have high miR569 levels (Fig-
ure 3E). Importantly, 3q26.2 amplification status and miR569
levels (Figure 1C) were inversely correlated with TP53INP1
protein levels in cell lines (Figure 4A), consistent with the conten-
tion that miR569 silences TP53INP1 expression. Furthermore,
tumors that arose from cells engineered to express miR569 (Fig-
ure 2) had decreased TP53INP1 levels (Figure S3A), again
supporting TP53INP1 as a miR569 target.
TargetScan predicted a single miR569 binding site in the
TP53INP1 30UTR (Figure S3B). Compatible with miR569 directly
binding to the TP53INP1 30UTR, miR569 markedly decreased
the activity of luciferase fused to the TP53INP1 30UTR in
both breast and ovarian cancer cells (Figure 4B). In contrast,
miR569 expression did not alter activity of luciferase linked to
a TP53INP1 30UTR where the putative miR569 binding site was
mutated (Figures S3C and S3D).
TP53INP1 Is Required for miR569 to Alter Cell
Proliferation and Viability
Although miR569 is not annotated in the mouse genome, se-
quences complementary tomiR569 seed sequences are present
in the murine Tp53inp1 30UTR (Figure S3E). Importantly, miR569
increased proliferation of wild-type (WT) mouse embryonic fibro-
blasts (MEFs) but not Tp53inp1-deficient MEFs (Figures 4C and
4D; Figure S3F). Furthermore, miR569 expression reduced
Tp53inp1 mRNA and TP53INP1 protein levels in WT MEFs (Fig-
ures 4E and 4F). BecausemiR569 is not expressed in mouse, we
determined whether TP53INP1 is required for the effects of
anti-miR569 in human cells. Anti-miR569 did not alter TP53INP1
expression or cell death in murine cells (Figures S3G–S3I)
consistent with the effects of anti-miR569 being specific to
miR569. In contrast, knockdown of TP53INP1 abolished the
effects of anti-miR569 on cell death in miR569-expressing hu-
man cells (Figures S3J–S3L). Importantly, miR569 reduced the
activity of p53 as well as the promoter activity of the p53 target
gene PERP in WT MEFs and HEYA8, but not in Tp53inp1/
MEFs (Figures S3M and S3N). Together, these results support
that TP53INP1 is required for the effects of miR569.
Next, we used 3D cultures on extracellular matrix to mimic
in vivo conditions. In 3D culture, MCF10A breast and MCAS
ovarian epithelial cells evolve into150 mm single-layered acinarFigure 2. miR569 Promotes Tumor Growth and Metastasis In Vivo
(A) IGROV1 cells stably expressing miR569 or control miR by lentiviral transductio
SD of triplicates. Significance was calculated with Student’s t test.
(B)MDAMB231 stably expressingmiR569 or control miR by lentiviral transduction
of triplicates.
(C and D) IGROV1 cells stably expressing miR569 or control miR were injected i
isolated on day 35 and number of abdominal tumors (C) and tumor weight (D) a
Student’s t test.
(E and F) MDAMB231 stably expressing miR569 or control miR were injected into
calculated at indicated time points (E, n = 8 per group). On day 25, tumors were is
calculated with Student’s t test.
(G and H) Representative immunohistochemical staining (G) and statistical analy
represent 50 mm. Bars represent SD of triplicates. Significance was calculated w
(I) Sites of tumor growth from mice in (C) and (D).
(J) Haematoxylin and eosin staining of six lung tissues isolated from (E); black arro
on the right of indicated groups.
(K) Metastasis incidence of mice in (E). Significance was by Fisher’s exact test. N
See also Figure S2.
Castructures with a hollow lumen through death of luminal cells
(Muranen et al., 2012; Pradeep et al., 2012a). Strikingly
miR569-transfected breast and ovarian epithelial spheroids
had decreased TP53INP1 expression and generated multilay-
ered cell structures consistent with decreased death of cells in
the lumen (Figures 4G–4I; Figures S3O–S3Q). Of note, siRNA-
mediated knockdown of TP53INP1 in MCAS spheroids was suf-
ficient to mimic the effects of miR569 with a marked increase in
the number of multilayered spheroids (Figures S3R–S3T), rein-
forcing the contention that TP53INP1 is a key target of miR569.
The effects of miR569 in 3D culture suggested that miR569
could alter self-renewal or tumor-initiating capacity (TIC).
Indeed, miR569 altered levels of markers associated with TICs
including increased CD44, CD133, and VIM (vimentin) and
decreased CDH1 (E-cadherin) in MCAS cells and increased
CD44 and VIM and decreased CDH1 in MCF10A cells. Whereas
miR569 increased the number of MCAS spheroids in 3D culture,
it was sufficient to increase the self-renewal capacity of MCF10A
cells in serial passages (Figures 4J and 4K; Figures S3U and
S3V), consistent with a role in TIC in MCF10A cells.
TP53INP1 Expression Is Regulated by p53, p73, and
NF-kB
Although p53 is the major transcriptional regulator of TP53INP1
(Okamura et al., 2001; Tomasini et al., 2001), TP53INP1 can
also be regulated by p73 in a p53-independentmanner (Tomasini
et al., 2005). TP53 is almost universally mutated in high-grade
serousovarian cancers but less frequentlymutated in breast can-
cers (Cancer Genome Atlas Research Network, 2012; Gasco
et al., 2002; Greenblatt et al., 1994). Importantly, TP53INP1 levels
were decreased in TP53-mutated breast cancers in four different
patient data sets (n = 757, Figures S4A and 7I). In addition to p53
and p73 binding sites, there are consensus NF-kB and N-Myc
binding sequences in the TP53INP1 promoter (Figure S4B).
In IOSE-80, knockdownof p53orp73 reducedTP53INP1expres-
sion, whereas knockdown of NF-kB1 or N-Myc had no effect
(Figure 5A). Cotransfection of miR569 with either p53 or p73
siRNA decreased TP53INP1 levels consistent with miR569
regulating TP53INP1 induced by p53 or p73 (Figure 5B). Impor-
tantly, knockdown of either p53 or p73 increased cell growth
moderately, with coordinate knockdown of p53 and p73 further
enhancing IOSE-80 cell proliferation (Figures 5B and 5C).n were harvested for qRT-PCR to analyze miR569 expression. Bars represent
were harvested for qRT-PCR to analyzemiR569 expression. Bars represent SD
nto the peritoneal cavity of female nude mice (n = 10 per group). Tumors were
ssessed. Bars represent SEM and significance was calculated with unpaired
mammary fat pads of female nude mice (n = 8 per group); tumor volume was
olated and tumor weight determined (F). Bars represent SEM. Significance was
sis (H; n = 3) of CD31 and Ki67 of tumors from mice in (C) and (D). Scale bars
ith Student’s t test.
ws indicate metastases to the lung. Black squares are magnified and displayed
D, not detected.
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siRNA increased growth of IOSE-80 cells to levels comparable
to concurrent knockdown of p53 and p73. Importantly, miR569
did not further increase cell growth with concurrent p53 and
p73 knockdown (Figures 5B and 5C) likely due to cells with con-
current p53 and p73 knockdown having insufficient TP53INP1 to
manifest the effects of miR569. These results were recapitulated
in Trp53/ or Trp73/ MEFs, where deletion of either Trp53 or
Trp73 reduced expression of Tp53inp1 mRNA, whereas double
knock-out Trp53/;Trp73/ MEFs (Flores et al., 2002) ex-
pressed the lowest amounts of Tp53inp1 (Figure 5D). Similarly,
transfection of miR569 increased proliferation of Trp53/ or
Trp73/ MEFs but not double knockout MEFs (Figure 5E).
In HEYA8 cells, which expressWT p53 (Figures S4C and S4D),
knockdown of p53, p73, or NF-kB decreased TP53INP1 expres-
sion (Figure 5F). In OVCAR5, CaOV3, or SKOV3 p53 mutant
ovarian cancer cell lines, knockdown of p73 or NF-kB1 but
not p53 decreased expression of TP53INP1 (Figure 5G; Fig-
ure S4E). Thus p53, or p73 and other transcription factors
including NF-kB or possibly N-Myc, albeit not in the cells as-
sessed herein, can contribute to transcriptional regulation of
TP53INP1 under different contexts, which is further downregu-
lated by miR569.
Silencing of miR569 Sensitizes Cells to Chemotherapy-
Induced Cell Death
We next determined whether miR569 alters sensitivity to
cisplatin, the most commonly used drug in ovarian cancer and
an emerging therapy for basal-like breast carcinoma. Of note,
miR569 expression reduced the sensitivity of normal breast
and ovarian epithelial cells to cisplatin (Figure 6A). Isobologram
analysis showed synergistic activity of the anti-miR569 and
cisplatin combination (Figure S5A). In HEYA8 (Figure 6B; Fig-
ure S5B) and OVCAR5 (Figure S5C) that have detectable
TP53INP1 basal levels, cisplatin alone increased TP53INP1,
which was augmented by anti-miR569. TP53INP1 can induce
phosphorylation of p53Ser46, which contributes to stress-
induced apoptosis in cancer cells (Okamura et al., 2001; Toma-
sini et al., 2003). As expected, both cisplatin and knockdown of
miR569 increased p53Ser46 phosphorylation, cleaved caspase-
3 and PARP, which increased further with the combination of
cisplatin and anti-miR569 (Figure 6B; Figures S5C and S5D).
Furthermore, anti-miR569 induced increases in p53Ser46 phos-
phorylation were paralleled by increases in total p53, PUMA,
Bax, P53AIP1, and p21 proteins that regulate apoptosis and
the cell cycle (Figure 6B).
As predicted, anti-miR569 modestly decreased cell survival
and sensitized HEYA8 to cisplatin-induced apoptosis in both
anchorage dependent and independent conditions (Figure 6C;Figure 3. Integrative Genomic Approach Identifies TP53INP1 as a Targ
(A) Venn diagrams of putative miR569 targets predicted by TargetScan and high
(B) IOSE-80 cells were transfectedwith control miR ormiR569 and total RNA isolat
were assessed by qRT-PCR and normalized to ACTB mRNA. Bars represent S
miR569 treated group with control.
(C) Black lines indicate active miR569 target sites on the TP53INP1 30UTR in 6 o
(D) IOSE-80 and MCF10A transfected with control miR or miR569 for 48 hr were
(E) HEYA8 and OVCAR5 transfected with control miR or miR569 for 48 hr were l
See also Tables S2, S3, and S4.
CaFigures S5E and S5F). Notably, knockdown of TP53INP1,
P53AIP1, and PUMA, but not NOXA, decreased anti-miR569-
induced caspase activity and cell death and concurrently
increased sphere forming ability of ovarian cancer cells (Figures
S5G–S5J) while decreasing miR569-induced sensitization to
cisplatin (Figures 6D and 6E). Importantly, knockdown of
TP53INP1 completely reversed cell death and caspase activity
induced by anti-miR569, while siRNA specific to PUMA or
P53AIP1 partially reduced cell death induced by anti-miR569,
consistent with TP53INP1 being a direct target of miR569 and
with P53AIP1 and PUMA acting downstream of TP53INP1 (Fig-
ure S5I). To further assess the specificity of anti-miR569,
HEYA8 stably expressing miR569 or control miR were trans-
fected with control anti-miR or anti-miR569 and were treated
with cisplatin. Strikingly, stable expression of miR569 markedly
attenuated cisplatin-induced increases in TP53INP1, phosphor-
ylated p53Ser46, p53, and PUMA, and increased colony forma-
tion, which were only partially reversed by anti-miR569 (Figures
S5K–S5M). Thus, overexpression of miR569 is able to at least
partially reverse effects of anti-miR569 consistent with the ef-
fects of anti-miR569 being on target.
Consistent with activation of caspase-3 and increased cell
death, anti-miR569 and cisplatin induced cytochrome C release
from mitochondria (Figure 6F; Figure S5N). Furthermore, anti-
miR569 combined with cisplatin augmented cytochrome C
release compared to each agent alone (Figure S5N). Cyto-
chrome C release induced by anti-miR569 was inhibited by
knockdown of p53AIP1 or TP53INP1, compatible with P53AIP1
or TP53INP1 being required for optimal anti-miR569-induced
apoptosis (Figure 6F; Figure S5O). Together, the data support
a model wherein gain of 3q26.2 copy number increases
miR569 levels that in turn decrease TP53INP1 (Figure 6G) limiting
the ability of stress, including chemotherapy-induced stress, to
activate p53, p73, or NF-kB and induce proapoptotic proteins
such as Bax, P53AIP1, and PUMA with subsequent cleavage
of caspase-3 and PARP.
miR569 Copy Number Changes and TP53INP1
Expression Are Associated with Ovarian and Breast
Cancer Outcomes
Because TP53INP1 is required for the effects of miR569, we
determined whether TP53INP1 levels correlate with patient out-
comes. Indeed, decreased TP53INP1mRNA levels were associ-
ated with worsened outcome (Figure 7A) in ovarian cancer
(Tothill et al., 2008). Immunohistochemical analysis confirmed
association of TP53INP1 levels with worsened patient outcomes
(Figure 7B) and reduced TP53INP1 protein in ovarian cancer
cells compared to normal epithelial cells (Figure 7C). Importantly,
TP53INP1 mRNA expression was markedly reduced in ovarianet of miR569
confidence targets identified with AGO-CLIP.
ed after 24 hr. Seventeen genes common to Targetscan and AGO-CLIP from (A)
D of triplicates. Significance was calculated with Student’s t test comparing
ut of 14 AGO-CLIP publicly available data sets.
lysed for immunoblotting with indicated antibodies.
ysed for immunoblotting.
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Furthermore, reduced TP53INP1 expression was observed in
invasive ovarian cancers compared to low malignant potential
tumors (Figure S6A) and miR569 levels were increased in late
compared to early stage ovarian cancers (Bagnoli et al., 2011)
(Figure S6B).
In breast cancer samples, 3q26.2 copy number gain also
associated with decreased TP53INP1 mRNA levels (Figure 7E).
Furthermore, gain of miR569 copy number as well as decreased
TP53INP1 mRNA levels were significantly more common in
basal-like breast cancers than in other breast cancer subtypes
(Figures S6C–S6E). Similar to ovarian cancer, elevated miR569
copy number (Figure 7F) and decreased TP53INP1 protein levels
(Figure 7G) were associated with worsened outcome in breast
cancer. In an independent cohort of breast cancers (Pawitan
et al., 2005) and a merged data set from three independent
breast cancer cohorts (Enerly et al., 2011; Haakensen et al.,
2010; Langerød et al., 2007; Muggerud et al., 2010; Naume
et al., 2007), low TP53INP1 mRNA levels were associated with
worsened outcomes (Figure 7H; Figure S6F).
The almost universal mutation of TP53 in high-grade serous
ovarian cancer precluded exploration of the role of TP53 muta-
tion in regulating expression of TP53INP1 or whether TP53
mutation alters effects of the TP53INP1 on ovarian cancer out-
comes. However, as predicted by the role for p53 in regulation
of TP53INP1, TP53-mutated breast cancer samples demon-
strated lower TP53INP1 mRNA and protein levels in the TCGA
breast cancer data set and mRNA levels in three independent
breast cancer cohorts (Enerly et al., 2011; Haakensen et al.,
2010; Langerød et al., 2007; Muggerud et al., 2010; Naume
et al., 2007) (Figure 7I; Figure S4A). Tumors with increased
miR569 copy number and mutated TP53 had lower TP53INP1
mRNA levels, suggesting that the two events collaborate to
decrease TP53INP1 (Figures 7I and 7J; Figures S6G–S6I).
miR569 copy number gain was associated with a poor outcome
in patients with WT TP53 (Figure 7K) and showed a trend to as-
sociation with poor overall outcome in patients with mutant p53
(Figure S6J). This is consistent withmutant p53 ormiR569 ampli-
fication decreasing TP53INP1 levels.Figure 4. miR569 Regulates TP53INP1 Expression by Binding the 30UT
(A) Immunoblot of TP53INP1 level and 3q26.2 copy number status of indicated c
Figure 1C).
(B) TP53INP1 30UTR luciferase reporter construct (top) was cotransfected with c
assessed (bottom). Bars represent SD of quadruplicates. Significance was calcu
(C) Wild-type (WT) or Tp53inp1 knockout (KO) MEFs were lysed and immunoblo
(D)WT or Tp53inp1KOMEFswere transfected with control miR ormiR569. Cell via
by Student’s t test comparing miR569 treated with control.
(E) mRNAwas extracted fromWT or Tp53inp1KOMEFs 24 hr after transfection wi
normalized to that of Actb mRNA. ND, not detected.
(F) Immunoblots of WT MEFs transfected with control miR or miR569.
(G) MCF10A grown as spheroids in 5%Matrigel for 12 days were transfected with
stained using DAPI. Images were captured using confocal microscopy. Scale ba
(H and I) TP53INP1 (H) or miR569 (I) levels of MCF10A spheroids transfected wit
mRNA or U6 RNA control, respectively. Bars represent SD of triplicates. Signific
(J) MCF10A grown in 5% Matrigel for 12 days were transfected with control m
spheroids and expression of target genes assessed by qRT-PCR and normalized
was calculated with Student’s t test.
(K) Spheroids grown as described in (J) were trypsinized and replated twice after 1
Bars represent SD of triplicate determinations. Significance was calculated with
See Figure S3.
CaWe explored whether p53 was required for effects of
TP53INP1 on patient outcomes in breast cancers, where only a
subset of tumors have TP53 mutations. Strikingly, in 75 TP53
mutant breast cancers from three independent cohorts (Haaken-
sen et al., 2010; Langerød et al., 2007; Muggerud et al., 2010;
Naume et al., 2007), TP53INP1 levels predicted patient out-
comes (Figure S6K). For reasons that are not clear, but poten-
tially due to short-term follow-up of TCGA samples, the effects
of TP53INP1 on outcomes of patients with WT TP53 in TCGA
breast cancer data set showed a trend to poor outcomes with
no association with outcomes in other cohorts assessed (Haa-
kensen et al., 2010; Langerød et al., 2007; Muggerud et al.,
2010) (data not shown). In breast cancer, WT TP53 was associ-
ated with improved survival when five previously published
breast cancer data sets were combined (Figure S6L). Intriguingly
patients with tumors having both WT TP53 and high TP53INP1
levels showed remarkably improved breast cancer specific sur-
vival particularly in comparison to patients with low TP53INP1
and mutant TP53 (Figure S6M).
Silencing of miR569 Inhibits Tumor Growth and
Metastasis in an Orthotopic Ovarian Cancer Model
To explore whether miR569 represents a potential therapeutic
target, we incorporated anti-miR569 into neutral liposomes
(1,2-dioleoyl-sn-glycero-3-phosphotidylcholine-DOPC) (Landen
et al., 2005) and treated HEYA8 or OVCAR5 cells, which
endogenously express miR569, orthotopic xenografts with and
without cisplatin. Both anti-miR569 and cisplatin decreased tu-
mor growth. Remarkably, the combination of anti-miR569 and
cisplatin induced a massive decrease in tumor weight and
number of tumor sites in the peritoneal cavity (Figures 8A
and 8B; Figure S7A). Consistent with in vitro studies (Figure 6),
anti-miR569 treatment significantly reduced miR569 levels
and increased both TP53INP1 and P53AIP1 mRNA levels.
Cisplatin treatment moderately increased TP53INP1 mRNA
and P53AIP1 mRNA as well as TUNEL staining as a marker of
cell death. Noticeably, combined treatment with anti-miR569
and cisplatin further increased TP53INP1 and P53AIP1 mRNA
expression and TUNEL positivity (Figures 8C–8F; Figures S7BR and Controls Proliferation of Breast and Ovarian Cells
ell lines. N and A represent 3q26.2 nonamplified or amplified, respectively (see
ontrol miR or miR569 into MDAMB231 or SKOV3 and luciferase activity was
lated with Student’s t test. *p% 0.01, **p < 0.005, and ***p < 0.0005.
tted with TP53INP1 and RASGAP (loading control) antibodies.
bility was assessed on day 4. Bars represent SD of triplicates. Significance was
th control miR ormiR569. Tp53inp1mRNA level was analyzed by qRT-PCR and
control miR or miR569 and cultured for another 72 hr. Spheroids were fixed and
rs represent 100 mm.
h control miR or miR569 were analyzed by qRT-PCR and normalized to ACTB
ance was calculated with Student’s t test.
iR or miR569 and cultured for another 72 hr. Total RNA was extracted from
to ACTB mRNA. Bars represent SD of triplicate determinations. Significance
2-day intervals. Number of spheroids (%) formed in each cycle was quantified.
Student’s t test.
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Figure 5. miR569 Exerts Growth Effects by
Altering Expression of TP53INP1 Induced by
p53 or p73
(A) IOSE-80 cells were lysed 48 hr after transfection
with control or indicated siRNA, and TP53INP1
mRNA expression was quantified by qRT-PCR and
normalized to ACTB mRNA. Bars represent SD
of triplicates. Significance was calculated with
Student’s t test.
(B) IOSE-80 cells were transfected with control miR
or miR569 24 hr after transfection with siRNA spe-
cific to p53 or p73 or both. Cells were lysed 48 hr
after miR569 transfection and immunoblotted with
the indicated antibodies.
(C) IOSE-80 cells were transfected as indicated in
(B) and viable cell number monitored 72 hr after
miR569 transfection using MTT. Bars represent SD
of quadruplicates. Significance was calculated with
Student’s t test.
(D) Total RNA was extracted from MEFs from
knock-out mice: Trp53/, Trp73/, or Trp53/:
Trp73/ (DKO). Tp53inp1 expression was
analyzed by qRT-PCR and normalized to Actb
mRNA. Bars represent SD of triplicates. Signifi-
cance was calculated with Student’s t test. *p %
0.005 compared to Trp53/ or Trp73/ MEFs.
(E) Cell viability of MEFs described in Figure 4D was
assessed 72 hr after transfection with miR569 or
control miR. Bars represent SD of quadruplicates.
Significance was calculated with Student’s t test.
(F and G) HEYA8 (F) or OVCAR5 (G) were lysed 48 hr
after transfection with control or indicated siRNA.
TP53INP1 mRNA quantified by qRT-PCR. Bars
represent SD of triplicates. Significance was tested
calculated with Student’s t test. *p < 0.01, **p <
0.005 compared to control siRNA.
See Figure S4.
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miR569 Aberration in Epithelial Oncogenesisand S7C). Anti-miR569 and cisplatin alone decreased levels of
Ki67 proliferation and CD31 endothelial cell markers whereas
combined treatment with anti-miR569 and cisplatin further
reduced Ki67 and CD31 (Figures 8E and 8F; Figure S7B).
Similar to the effects on ovarian cancer models, anti-miR569
treatment reduced volume and weight of tumors derived from
MDAMB231 that express high levels of miR569 (Figures S7D–
S7G). Of note, liposomal delivery of anti-miR569 did not induce
apoptosis or reduce tumor burden or metastasis when injected
in mice bearing IGROV1 that do not have an elevated miR569
copy number (Figures S7H and S7I).
TP53INP1 Is Sufficient and Necessary for the Effects of
Anti-miR569
Our data suggest that the effects of miR569 are dependent on
the ability to alter TP53INP1 levels. To test this contention
in vivo, we determined the effect of altering TP53INP1 levels
on intraperitoneal HEYA8 growth. As predicted, expression of
TP53INP1 in HEYA8 decreased both number and size of tumors,872 Cancer Cell 26, 863–879, December 8, 2014 ª2014 Elsevier Inc.recapitulating the effects of anti-miR569
in vivo (Figures S7J–S7L). In contrast, tran-
sient or stable knockdown of TP53INP1
abolished the ability of anti-miR569 to
decrease cell growth in vitro (FiguresS5G, S7M, and S7N) and abolished the ability of anti-miR569
to decrease HEYA8 growth in vivo (Figures 8G and 8H). Taken
together, the results show that TP53INP1 is a key target of
miR569 both in vitro and in vivo.
DISCUSSION
Our studies demonstrate that copy number alterations of the
3q26.2 amplicon are associated with increased miR569 expres-
sion in ovarian and breast cancers. The increase in miR569
levels subsequently decreases TP53INP1 levels. Through down-
regulation of TP53INP1, miR569 increases cell proliferation,
anchorage-dependent and -independent cell growth, allows
the formation of multilamellar cellules, and increases tumor
growth and metastasis in vivo. Intriguingly, anchorage-indepen-
dent growth and ability to maintain cell survival in multilamel-
lar cellules require a coordinate decrease in apoptosis and
improved metabolic performance (Schafer et al., 2009). Thus,
miR569 may affect both processes required for survival under
A B C
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Figure 6. Anti-miR569 Sensitizes Ovarian Cancer Cells to Cisplatin Treatment
(A) IOSE-80 and MCF10A were transfected with control miR or miR569 24 hr prior to cisplatin treatment at indicated concentrations. Cell viability was monitored
72 hr after transfection using MTT. Bars represent SD of triplicates. Significance was by two-way ANOVA.
(B) HEYA8 (WT TP53) transfected with control antimiR or anti-miR569 for 48 hr were treated with cisplatin for another 8 hr before immunoblotting using indicated
antibodies.
(C) HEYA8 cells grown on low attachment plates in low density for 7 days were transfected with control antimiR or anti-miR569 for another 48 hr prior to addition of
cisplatin (top). Colonies were photographed 4 days after cisplatin addition (bottom). Scale bars represent 100 mm. Number of colonies formed was quantified.
Bars represent SD of triplicates. Significance was calculated with Student’s t test. *p% 0.005, **p < 0.001.
(D and E) HEYA8 cells were transfected with control or TP53INP1 specific siRNA 24 hr prior to antimiR transfection. Cells were treated with 10 mM cisplatin for
48 hr after antimiR transfection, lysed and immunoblotted using indicated antibodies (D), and cell death was assessed using a cell death ELISA 72 hr after antimiR
treatment (E). Bars represent SD of quadruplicates. Significance was calculated with Student’s t test. *p < 0.001, **p < 0.0001 compared to control oligo
transfected group without cisplatin. #p < 0.01 compared to cisplatin or anti-miR569 group.
(legend continued on next page)
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expression of TP53INP1 in the tumorigenic MiaPaCa2 pancreatic
cancer cell line abolished tumor-forming ability in nude mice
through induction of caspase-3-mediated apoptosis (Gironella
et al., 2007), and mice deficient in Tp53inp1 were susceptible to
colitis-associated carcinogenesis (Gommeaux et al., 2007).
The observation that miR569 was elevated as a consequence
of the 3q26.2 amplicon and associated with decreased
TP53INP1 in ovarian cancer raised a number of questions given
that p53 transcriptionally regulates TP53INP1 and TP53 is almost
universally aberrant in high-grade serous ovarian cancer. Impor-
tantly, some TP53 mutations contribute to tumor progression
through the acquisition of ‘‘gain-of-function’’ properties, which
may explain the effects of miR569 (Freed-Pastor and Prives,
2012; Oren and Rotter, 2010). Furthermore, we show that p73
or NF-kB can transcriptionally regulate the expression of
TP53INP1 independent of p53. Compatible with this contention,
TP53INP1 levels were associated with outcomes in patients with
high-grade serous ovarian cancers where TP53 is almost univer-
sally mutant as well as in the subset of breast cancers with TP53
mutations. Indeed, across multiple data sets, TP53INP1 mRNA
and proteins levels were associated with improved patient out-
comes consistent with the ability of TP53INP1 to regulate
apoptosis as well as the ability of miR569 to alter proliferation,
anchorage independence, and multilamellar cellule formation.
It is unclear why manipulation of p53 altered proliferation and
TP53INP1 levels in SV40 T-Ag transformed IOSE cells. However,
a portion of p53 may not be completely inactivated by T-Ag and
could potentially activate TP53INP1 transcription directly (Dep-
pert and Steinmayer, 1989; Sheppard et al., 1999). Alternatively,
p53 complexed with T-Ag may form a functional complex with
p63 or p73 thus regulating TP53INP1 transcription (Urist and
Prives, 2002).
The discovery that microRNAs are potent regulators of RNA
stability and translation dramatically changed our understanding
of the mechanisms controlling protein levels, and further pro-
vided a potential therapeutic approach to a number of targets
that have previously been designated ‘‘undruggable.’’ However,
the translation of miR therapy to the clinic is in its infancy. Based
on the effects of anti-miR569 in vitro and in vivo on cell survival in
the presence and absence of cisplatin, themost commonly used
drug in ovarian cancer, an approach to decrease miR569 activity
or increase TP53INP1 levels warrants exploration in ovarian and
breast cancers. An ability to translate the in vivo anti-miR ap-
proaches used in the animal models herein to the patient would
thus be highly attractive. Indeed, such studies are currently
underway at the MD Anderson Cancer Center.
EXPERIMENTAL PROCEDURES
Patient Samples
After informed consent, normal ovarian epithelial tissues and serous epithelial
ovarian cancer tissues were collected according to an Institutional Review
Board approved protocol at the MD Anderson Cancer Center. Normal ovarian(F) HEYA8 were transfected with siRNAs specific to TP53INP1 or P53AIP1 24 hr pr
after antimiR transfection. Cytosolic fractions were prepared and cytochrome C
compared to control antimiR transfected group without cisplatin.
(G) Proposed model illustrates deregulation of cell cycle and proliferation by miR
See Figure S5.
874 Cancer Cell 26, 863–879, December 8, 2014 ª2014 Elsevier Inc.tissues were from the tumor-free ovary of patients with unilateral ovarian can-
cer or patients with other gynecological cancers not involving the ovary. After
informed consent, normal fallopian tube tissue samples were collected ac-
cording to an Institutional Review Board-approved protocol at the Harvard
Cancer Center.
RNA Isolation and miR Detection
Total RNA from cultured cells, with efficient recovery of small RNAs, was iso-
lated using the mirVana miR Isolation Kit (Ambion). Detection of mature miR
was performed using cDNA generated with QIAGEN miScript kit and subse-
quent qRT-PCR analysis with SYBR Green I (QIAGEN) according to manufac-
turers’ instructions. Primers specific to mature microRNA sequences were
from QIAGEN. The U6 small nuclear RNA (RNU6B) was used as internal
normalization control.
MicroRNA Gene Overexpression
Human miR569 cloned into pEZX-MR06 lentiviral vector was from GeneCo-
poeia. Production of amphotropic viruses and infection of target cells were
described previously (Stewart et al., 2003).
Oligonucleotide Transfection
The miRIDIAN microRNA mimics, double-stranded oligonucleotides de-
signed to overexpress miRs, siRNAs targeting TP53INP1 and P53AIP1 (Dhar-
macon) and antimiR (Ambion) were transfected using Oligofectamine
(Invitrogen).
AGO-PAR-CLIP Data Analysis
AGO-PAR-CLIP data analysis was performed as described previously (Hamil-
ton et al., 2013). Detailed experimental procedures are provided in the Supple-
mental Experimental Procedures.
Cell Viability Assay
Cell viability (survival) was determined by a 2 hr incubation with 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), followed by lysis in
acidic isopropanol (0.35% HCl in isopropanol) and measurement of absor-
bance at 570 nm. Cell viability was calculated as increase in MTT signal
compared to MTT signal on Day 0 prior to treatment.
Morphogenesis Assay
Morphogenesis assays and anchorage-independent growth assays were per-
formed as described previously (Pradeep et al., 2012a; Pradeep et al., 2012b).
For 3D culture assays, trypsinized cells were resuspended in Dulbecco’s
modified Eagle’s medium/F12 medium supplemented with 2% horse serum.
Eight-chambered plates (BD Biosciences) were coated with 35 ml growth
factor reduced Matrigel (BD Bioscience) per well. Cells were mixed with me-
dium containing 4% Matrigel and plated at a final volume of 400 ml in each
chamber.
Reverse-Phase Protein Arrays
Reverse-phase protein array analysis was performed as described previously
(Hennessy et al., 2010) and detailed at http://www.mdanderson.org/
education-and-research/resources-for-professionals/scientific-resources/
core-facilities-and-services/functional-proteomics-rppa-core/index.html.
Indirect Immunofluorescence
Immunofluorescence analysis of acini was performed as described previously
(Pradeep et al., 2012a). Acini were fixed in methanol-acetone and blocked in
10% goat serum. Secondary blocking was performed in buffer containing
goat anti-mouse F(ab0)2 fragments (20 mg/ml). Primary antibodies were incu-
bated for 15–18 hr at 4C and secondary antibodies for 1 hr before confocal
microscopy.ior to transfection with antimiR. Cells were treated with 10 mMcisplatin for 48 hr
quantitated by ELISA. Bars represent SD of triplicates. *p < 0.01, **p < 0.005
569.
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Figure 7. miR569 Copy Number Changes and TP53INP1 Expression Are Associated with Ovarian and Breast Cancer Outcomes
(A) Kaplan-Meier plot of recurrence-free survival (RFS) of 275 patients with ovarian cancer (Tothill et al., 2008) stratified by high or low TP53INP1 expression in
tumor.
(B) Kaplan-Meier plot of overall survival of 89 patients with ovarian cancer stratified by high or low TP53INP1 protein levels in their tumors determined by
immunohistochemistry (IHC). Log-rank test was used to compare differences between groups.
(C) IHC images of TP53INP1 expression in ovarian cancer tissue and normal tissue. Scale bars represent 50 mm.
(D) TP53INP1 expression in 33 ovarian cancers assessed by qRT-PCR and normalized to ACTB mRNA. Box plot represents lower quartile; median and upper
quartile and whiskers represent the 95% confidence interval of the mean. Significance was calculated with Student’s t test.
(E) TP53INP1 mRNA levels in 521 TCGA breast cancer samples based on miR569 copy number levels. Box plot represents lower, median, and upper quartiles.
Whiskers represent the upper or lower quartile plus 1.5 times the interquartile range. Significance was calculated with two-tailed Student’s t test.
(F) Kaplan-Meir analysis of overall survival based on miR569 copy number alterations from TCGA (n = 829). Significance was calculated with log-rank test.
(G) Kaplan-Meier plot of overall survival of 410 patients with breast cancer based on tumor TP53INP1 protein levels from TCGA RPPA data. Significance was
calculated with log-rank test.
(H) Kaplan-Meier plot of recurrence-free survival of patients with breast cancer (n = 159) stratified by high or low TP53INP1mRNAexpression in a published breast
cancer data set (Pawitan et al., 2005). Significance was calculated with log-rank test.
(I) Expression of TP53INP1mRNA and protein levels in TCGA breast cancer data of TP53mutated (Mut) or wild-type (WT) samples. Significance was calculated
with two-tailed t test.
(J) miR569 copy number alterations in TCGA breast cancer data of TP53Mut or WT samples. Significance was calculated with two-tailed t test. Box plot in (I) and
(J) represents lower, median, and upper quartiles. Whiskers represent the upper or lower quartile plus 1.5 times the interquartile range.
(K) Kaplan-Meir plot of overall survival based onmiR569 copy number alterations of 306 breast cancer tumorswithWT TP53 from TCGA breast cancer data. Note:
size of TCGA sample sets vary due to availability of data and changes in analysis platforms.
See Figure S6.
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Cells were transfected with reporter plasmids or control vector using Lipofect-
amine 2000 (Invitrogen). Twenty-four hours after transfection, cells wereCawashed twice with PBS and then lysed and luciferase activity measured using
luciferase assay substrate (Promega) according to the manufacturer’s proto-
col using an Opticom II luminometer (MGM Instruments).ncer Cell 26, 863–879, December 8, 2014 ª2014 Elsevier Inc. 875
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Cytochrome-C release kit was from Kamiya Biomedical. Cells were collected
after treatment and suspended in cytosol extraction buffer mix containing pro-
tease inhibitors and incubated for 10 min on ice. Homogenates were collected
and centrifuged at 7003 g for 10 min at 4C. Supernatants were collected into
a fresh 1.5 ml tube, and centrifuged at 10,0003 g for 30 min at 4C. Superna-
tantswere collected and released cytochromeCwas assessed using an ELISA
kit from R&D Systems.
Analysis of Public Gene Expression Data Sets
TCGA ovarian cancer SNP, mRNA data, TCGA breast cancer reverse-phase
protein arrays, and clinical data were downloaded from the TCGA Data
portal (http://tcga-data.nci.nih.gov/tcga/findArchives.htm). ‘‘Amplification’’
was defined as gain of more than three copies and ‘‘copy number gain’’ as
gain of at least 0.5 copies, respectively. CNTools package from Bioconductor
(http://www.bioconductor.org/) was used to process SNP data. Cox propor-
tional hazard regression model was used for univariate survival analysis. Over-
all survival or recurrence-free survival was used as an endpoint. The cutoffs of
high expression and low expression were optimized to achieve the lowest p
value. Statistical analysis was performed using R Software.
Animal Studies
Female athymic nude mice were from the National Cancer Institute, Frederick
Cancer Research and Development Center. Animals were cared for according
to guidelines set forth by the American Association for Accreditation of Labo-
ratory Animal Care and the US Public Health Service policy on Human Care
and Use of Laboratory Animals. All mouse studies were approved and super-
vised by the MD Anderson Cancer Center Institutional Animal Care and Use
Committee.
Additional experimental protocols are described in the Supplemental Exper-
imental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.10.010.
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